Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 1.39 -0.08 (-5.10%)
price chart
Overhang on Sunesis Pharmaceuticals, Inc. Will Persist: Cantor
In a research report issued today, Cantor analyst Mara Goldstein reiterated a Hold rating on shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with a $2.00 price target, after the company reported its second-quarter earnings results, posting EPS of ...
Momentum Stock in Focus - Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)  Enterprise Leader
Stock's Buzzers: Juniper Networks, Inc. (NYSE:JNPR), Sunesis ...  wsnewspublishers
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 9.5%
The company had allegedly violated specific sections of the Securities Exchange Act of 1934 by issuing materially misleading information to the investing public.
GPM Announces Investigation of Sunesis Pharmaceuticals, Inc.  MarketWatch
Sunesis Pharmaceuticals Inc (SNSS) Files Form 4 Insider Selling : Steven B ...  Insider Trading Report
FDA seeks more clinical evidence on Sunesis Pharma cancer drug
Sunesis Pharmaceuticals Inc said the U.S. Food and Drug Administration called for more clinical evidence before considering approval for its cancer drug, sending the company's shares down 60 percent in after-market trading.
Analyst Downgrades: TripAdvisor Inc, TrueCar Inc, and Sunesis ...  Schaeffers Research (blog)
Cowen Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform
Investigation of Sunesis Pharmaceuticals, Inc. Announced by The Law Offices of ...
BENSALEM, Pa., Jul 24, 2015 (BUSINESS WIRE) -- Law Offices of Howard G. Smith announces an investigation on behalf of investors of Sunesis Pharmaceuticals, Inc. ("Sunesis" or the "Company") SNSS, +9.77% The investigation concerns whether the ...
Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) has been on the move lately as the stock has risen by 27.6% in the past four weeks, and it is currently trading well above its 20-Day SMA.
Analyst Rating Update on Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals (NASDAQ:SNSS) has received a short term rating of strong buy from research analysts at Zacks with a rank of 1. The company has been rated an average of 2.43 by 7 Wall Street Analysts. 3 analysts have added the shares in their ...
Active Stocks in Queue: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS ...
On Friday, Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), lost -72.36% to $0.96, hitting its lowest level. Sunesis Pharmaceuticals declared regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S.
Sunesis Pharmaceuticals, Inc. Analyst Price Target Update
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): The mean short term price target for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has been established at $3.2 per share. The higher price target estimate is at $6 and the lower price target estimate is ...
Notable Downgrades: TrueCar (TRUE), Sunesis Pharmaceuticals (SNSS), Constant ...
Sunesis Pharmaceuticals, Inc. (SNSS) was downgraded to 'Sell' from 'Buy' at Cantor Fitzgerald. The firm lowered their PT to $1 from $5.50 noting company provided the much anticipated regulatory updates from both the FDA and EMA with mixed results, ...
Biotech Stocks Attracting Some Extra Attention - Sunesis Pharmaceuticals ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rose +10.53% to end last trading session at $1.47. The company, on July 30, 2015, released financial results for the second quarter ended June 30, 2015.
Biotech Bulls: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Vertex ...  Stock Transcript